The Bioheart 3370 Heart Failure Monitor collects data from a range of vital sign monitoring devices, a weight scale and a voice-activated heart failure status questionnaire, and provides for secure data transmission to an HTTP server on the Internet. The monitor is designed with unique features that make the device state-of-the-art for system integrators working the area of home monitoring, e-health and remote disease management. Regular data input and monitoring enables the health care team to detect signs and symptoms of change as they occur.
"We are very excited about this tremendous opportunity to better serve the Congestive Heart Failure patient population and their physicians," said Howard J. Leonhardt, Bioheart's CEO and Chief Technology Officer. "This technology is highly synergistic to our work with MyoCell(R) Therapy, an investigational cell therapy for the potential treatment of chronic heart damage, and marks the beginning of our ability to offer new intelligent devices that complement cell transplantation."
On average, Class III heart failure patients are hospitalized on an emergency basis six days of every six months. One of the goals of both MyoCell(R) Therapy and the Bioheart 3370 At-Home Heart Failure Monitor is to significantly reduce the number of emergency hospitalization days, as well as their associated costs.
"The Bioheart 3370 Heart Failure Monitor is extremely simple and intuitive to use for elderly patients," said Bjarne Flou, CEO, RTX Healthcare. "We believe this partnership will deliver excellent value for patients and physicians."
The Bioheart 3370 At-Home Heart Failure Monitor will be available through physician prescription.
ABOUT CONGESTIVE HEART FAILURE
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved